• Mon - Fri 9.00 - 19.00
Open

Yearly Archives: 2026

Tamara News  /  Blog  /  2026
10 Sep 2026
Addis Ababa Ethiopia cityscape representing the USCIS Addis Ababa office opening

USCIS Just Opened Its Newest Office — And It’s Not in the US

Categories Immigration

USCIS opened a new international field office in Addis Ababa, Ethiopia, on September 9, 2026. The office gives applicants across the country direct access to immigration services without traveling to a different region or country for in-person appointments.

The Addis Ababa office joins a small network of USCIS international field offices that handle immigration matters for applicants living outside the United States. That includes interviews, biometrics collection and case processing that previously required travel to offices serving multiple countries at once.

USCIS international field offices operate differently from domestic ones, since they primarily serve applicants who are not physically present in the United States. Staff at these offices coordinate closely with US embassies and consulates in the region, since many immigration cases require both agencies to complete different parts of the same application.

What the USCIS Addis Ababa office actually does

International field offices handle a range of services for people abroad who are part of the US immigration system. Green card applicants going through consular processing use them. So do US citizens abroad seeking documentation for family members. In some regions, the offices also handle refugee or asylum-related processing. The Addis Ababa office specifically will manage USCIS immigration matters for cases originating in Ethiopia.

Passport and visa documents representing the USCIS Addis Ababa office opening

Before this office opened, applicants in Ethiopia seeking in-person USCIS services often had to travel to field offices in other countries. That added cost, time and logistical complexity to an already lengthy immigration process. A local office removes that travel requirement for many routine appointments.

Travel costs for overseas immigration appointments can run into hundreds of dollars once flights, lodging and lost work time are factored in. For applicants in lower-income households, that expense has historically been a real barrier to completing required in-person steps on schedule.

A missed or delayed appointment can push a case back by months in some circumstances. Immigration attorneys often advise clients to build extra buffer time into travel plans for exactly this reason. A local office reduces that risk simply by cutting the travel step out of the process entirely.

USCIS has not published projected wait times specific to the Addis Ababa office. Applicants can typically expect an early operational period. Scheduling usually stays more limited then than it will be once the office reaches its normal staffing level.

Why USCIS is expanding its international footprint

USCIS has periodically opened or reorganized international field offices to better match where applicant demand is concentrated. East Africa has seen significant immigrant and refugee case volume in recent years. Locating an office directly in Addis Ababa reflects that regional demand and follows a broader pattern of USCIS adjusting its overseas footprint based on caseload data.

The move comes at a time when the US immigration system overall is processing significant volume shifts. Changes to student visa rules and green card categories have drawn attention throughout 2026.

What applicants in the region should know

Applicants with pending cases connected to Ethiopia should watch official USCIS communications for guidance on whether their case will now go through the Addis Ababa office rather than a previous location. USCIS typically sends a direct notice, by mail or through the applicant’s online case status portal, whenever a case moves between offices.

The agency has not said whether the new office will expand services beyond its initial scope in its first months of operation. Applicants should rely on official USCIS channels rather than third-party guidance for case-specific instructions.

How this fits the region’s broader immigration picture

Ethiopia hosts one of the largest refugee and immigrant populations in East Africa, and demand for US immigration services in the country has grown steadily over the past several years. Applicants from neighboring countries have also historically routed cases through regional US immigration infrastructure when a dedicated local office did not exist. A dedicated Addis Ababa office may reduce that cross-border routing for Ethiopian nationals specifically, though the agency has not detailed whether the office will accept cases from applicants based in neighboring countries.

Immigration attorneys who work with East African clients say a local office typically shortens wait times for biometrics appointments and interviews, based on how similar new offices have performed elsewhere.

What happens as the office ramps up

New international field offices typically take time to reach full operating capacity. Appointment availability expands gradually as staff are trained and case backlogs are assessed. USCIS has not published a specific timeline for when the Addis Ababa office will reach its full intended caseload capacity.

Applicants should expect standard USCIS processing times to apply once the office is fully operational. Early adopters of a newly opened office sometimes experience longer initial wait times as systems and staffing stabilize.

Questions about the new office

  • When did the office open? September 9, 2026.
  • What services does it provide? USCIS immigration matters for cases originating in Ethiopia, including interviews and case processing.
  • Who benefits most from this office? Applicants in Ethiopia who previously had to travel to a different country for USCIS services.
  • Will my case automatically transfer there? USCIS typically notifies applicants directly if their case is reassigned to a new office.
  • Is this USCIS’s only office in East Africa? The agency has not published a full comparison of its regional office network alongside this announcement.
  • Where can applicants get official updates? Directly through USCIS’s website and official case status communications.

Related coverage on Tamara News

See our coverage of the October 2026 visa bulletin, the DV-2026 diversity visa deadline, and the public charge rule changes for green card applicants.

Sources

10 Sep 2026
Federal courthouse building representing the Tennessee sues Anthropic patent case

A University Foundation Says Anthropic Built Claude on Its Patents

Categories Tech

The University of Tennessee Research Foundation has sued Anthropic in federal court in Delaware. The foundation alleges the AI company’s systems infringe two patents covering neuroscience-inspired machine learning technology developed by university researchers. The complaint, filed in July 2026, marks the first patent-infringement case brought against Anthropic.

The foundation says the patents cover work in artificial intelligence, neural networks and neuromorphic computing invented by University of Tennessee professors. It is seeking unspecified damages along with an order blocking further alleged infringement.

Neuromorphic computing refers to hardware and software designed to mimic how biological brains process information, an approach that has influenced parts of modern machine learning research. University research foundations like the one at Tennessee typically manage patent portfolios generated by faculty and pursue licensing deals or litigation when they believe commercial use has occurred without proper authorization.

Research foundations attached to major universities often generate meaningful revenue through technology licensing, and litigation is generally treated as a last resort after licensing discussions fail to produce an agreement. Public court filings do not indicate whether the foundation attempted to negotiate a license with Anthropic before filing suit in July.

Delaware’s federal court handles a large share of US patent litigation involving technology companies, partly because many corporations are legally incorporated there. That makes the district a common venue choice for plaintiffs regardless of where the underlying dispute actually originated.

The foundation’s legal team has not publicly commented beyond the filed complaint itself. Cases at this early stage typically have no scheduling order for hearings yet, since courts usually wait for the defendant’s initial response before setting a timeline.

What the Tennessee sues Anthropic patent case actually claims

According to the foundation’s complaint, Anthropic’s AI systems rely on techniques covered by patents the university’s professors developed through their neuroscience-inspired machine learning research. The foundation manages intellectual property generated by University of Tennessee faculty. It argues that Anthropic’s commercial AI products incorporate this patented approach without a license.

Courthouse building representing the Tennessee sues Anthropic patent lawsuit

Patent infringement suits against AI companies have become more common. Universities, competitors and rights holders increasingly argue that the underlying research techniques powering large language models draw on their prior work without authorization or compensation.

Why this is a notable first for Anthropic

Anthropic has faced copyright disputes tied to training data in the past. This case is distinct because it targets the architecture and methods behind the technology itself, rather than the data used to train it. A successful patent claim could, in theory, affect how the underlying systems are built, not just how training material was sourced.

Anthropic has not yet filed a public response to the complaint. The company has not commented publicly on the specific allegations as of early September 2026.

What this means for the broader AI industry

Universities and research institutions increasingly hold patents covering foundational machine learning techniques developed decades before today’s commercial AI boom. The University of Tennessee Research Foundation’s suit could encourage similar claims from other institutions watching how this case unfolds. AI companies have generally licensed data and compute at scale but have paid less public attention to whether underlying architectural techniques carry patent obligations.

Legal analysts tracking AI litigation note that patent cases typically move more slowly than copyright disputes. They often take years to reach resolution through discovery, expert testimony and potential appeals.

What other universities are watching

Technology transfer offices at several major research universities have flagged AI patent litigation as an area to monitor closely, according to industry newsletters covering the space. Many universities hold older patents tied to neural network research from the 1990s and 2000s, long before commercial large language models existed. Whether those patents can be enforced against modern AI systems remains legally untested outside a small number of cases. A ruling in the Tennessee case, whichever way it goes, is likely to influence how other institutions weigh similar claims.

No other university has yet filed a comparable suit against Anthropic specifically. Legal observers say that could change depending on how this case develops over the coming months.

What happens next in the case

The case will proceed through the federal court system in Delaware, where Anthropic is expected to file a formal response addressing the infringement allegations. Discovery follows next, in which both sides exchange technical evidence about how the disputed methods were developed and used. That process can take many months in patent litigation of this complexity.

Neither party has indicated interest in an early settlement. Cases of this type frequently proceed toward trial unless a licensing agreement is reached beforehand.

Questions about the lawsuit

  • Who filed the lawsuit? The University of Tennessee Research Foundation.
  • When was it filed? July 2026, in federal court in Delaware.
  • What does the foundation allege? That Anthropic’s AI systems infringe patents covering neuroscience-inspired machine learning technology.
  • Is this the first patent suit against Anthropic? Yes, according to reporting on the case.
  • Has Anthropic responded? The company had not issued a public response to the specific allegations as of early September 2026.
  • What is the foundation seeking? Unspecified damages and an order blocking further alleged infringement.

Related coverage on Tamara News

See our coverage of the GPT-6 Astra release, the Nvidia chip export loophole story, and the Apple UK antitrust lawsuit.

Sources

  • WBIR — University of Tennessee Research Foundation sues Anthropic. wbir.com
  • U.S. News & World Report — Anthropic Sued for Infringing Neural Network Technology Patents. money.usnews.com

10 Sep 2026
Laptop browser screen representing the Chrome zero-day patch 2026 update

Google Just Patched Its Seventh Emergency Chrome Bug This Year — Update Now

Categories Tech

Google has shipped an emergency fix for a Chrome vulnerability that attackers were already exploiting before the patch went out. It marks the seventh actively-exploited zero-day the company has addressed in the browser so far in 2026. The update reached the stable channel on September 9, 2026. Google is urging users to update immediately rather than wait for automatic installation.

Zero-day vulnerabilities are flaws that attackers exploit before a vendor has released a fix, which makes them more dangerous than bugs discovered through routine testing. Google’s security team disclosed limited technical detail about the flaw. That is standard practice, meant to slow attackers from reverse-engineering the exploit before most users have patched.

Chrome ships updates through a staged rollout system, meaning not every user receives a new version at the exact same moment. Google typically pushes critical security fixes to the front of that queue, which is why officials describe emergency patches like this one as reaching most users within a day or two of release, faster than a routine feature update.

Enterprise IT teams often manage Chrome updates separately from consumer devices, using centralized policy tools to push patches across an organization’s fleet on a controlled schedule. Security teams generally treat a zero-day advisory as a trigger to override that normal schedule and push the fix immediately instead.

What the Chrome zero-day patch 2026 actually fixes

Google’s advisory confirmed attackers were exploiting the vulnerability in the wild. The company withheld specifics about which threat actors were behind the activity or how many users may have been targeted. Chrome’s security team typically restricts technical bug details until most of the browser’s user base has installed the update. For a browser with Chrome’s scale, that rollout can take days to weeks.

Encrypted network data visualization representing the Chrome zero-day patch 2026 fix

The seventh exploited zero-day of the year keeps Chrome roughly on pace with recent years. The browser has regularly logged a handful of actively-exploited flaws annually. That reflects both its scale as the world’s most-used browser and the resources attackers dedicate to finding weaknesses in it.

Why this keeps happening to the world’s most-used browser

Chrome’s dominant market share makes it a high-value target. A working exploit can potentially reach a huge number of devices before defenders catch up. Google runs a bug bounty program and an internal red team specifically to find these flaws before attackers do. Still, the sheer size of Chrome’s codebase, combined with its exposure to nearly every kind of web content, means new vulnerabilities surface regularly.

Security researchers say browsers remain one of the most attractive targets for both criminal groups and state-linked actors. A single successful exploit chain can bypass many other layers of a device’s security.

What users should actually do

Chrome typically updates itself automatically. Users can force an immediate check by opening the browser’s menu, selecting Help, then About Google Chrome, which triggers a check and installs any pending update. Chrome needs a relaunch to complete the patch. Leaving old browser tabs open without restarting does not apply the fix.

Users on Chromium-based browsers such as Microsoft Edge and Brave should also watch for their own vendor updates. Those browsers often need to incorporate the same underlying Chromium security fix separately.

How this compares with Chrome’s earlier 2026 patches

Chrome’s six previous zero-day patches this year followed a similar pattern: limited public detail at release, followed by fuller technical writeups once most users had updated. Security researchers who track browser vulnerabilities say the frequency is not unusual for a codebase Chrome’s size, though it can look alarming when tallied across a single year. Enterprise security teams have adjusted by treating every Chrome security bulletin as a same-day patching priority rather than folding it into routine update cycles. That shift has become common across large organizations managing thousands of endpoints.

Google’s Project Zero and its internal Chrome security team continue to publish periodic summaries of the year’s vulnerability trends, typically after each individual flaw has been fully patched across the user base.

What happens if you don’t update

Once a zero-day’s technical details become public, whether through Google’s own eventual disclosure or independent researcher analysis, the window for opportunistic attackers to build their own exploits widens considerably. Enterprises running managed Chrome deployments typically have a shorter runway to push the update across their fleets before that broader risk period begins.

Google has not indicated any plans to change its update cadence. Further security bulletins are expected to follow its standard monthly and out-of-band patching pattern for the rest of 2026.

Questions about the Chrome update

  • When was the patch released? September 9, 2026, on Chrome’s stable channel.
  • Is this the first zero-day Chrome has faced this year? No, it is the seventh actively-exploited zero-day Google has patched in Chrome in 2026.
  • How do I update Chrome manually? Open the browser menu, go to Help, then About Google Chrome, and restart when prompted.
  • Does this affect Chromium-based browsers like Edge? Those browsers typically need their own separate update to incorporate the same fix.
  • Has Google said who is behind the exploit? No, Google withheld details about the threat actors involved.
  • Is restarting the browser necessary? Yes, the update does not take effect until Chrome is relaunched.

Related coverage on Tamara News

See our coverage of the GPT-6 Astra release, the American Tower data breach, and the Sony PlayStation Store lawsuit.

Sources

10 Sep 2026
Biotech laboratory setting representing the Ultragenyx Angelman trial failure story

A Biotech Stock Lost Nearly Half Its Value in One Day — Here’s Why

Categories Business

Shares of Ultragenyx Pharmaceutical plunged more than 46% after the company reported that a Phase 3 trial of its drug candidate for Angelman syndrome failed to meet its primary endpoint. The drop wiped out a significant portion of the biotech’s market value in a single trading session in early September 2026.

Angelman syndrome is a rare genetic neurological disorder. Ultragenyx had positioned the trial as a key step forward. A success would have delivered one of the first approved treatments targeting the condition’s underlying genetic cause rather than only its symptoms.

The condition typically causes developmental delays, speech impairment and seizures. It stems from a loss of function in a single gene. That is why gene-targeted therapies like the one Ultragenyx tested had drawn significant attention from patient advocacy groups. Families affected by Angelman syndrome had closely followed this trial’s progress over the past several years.

Ultragenyx built its business around rare genetic disorders long before this trial began. The company has brought several approved therapies to market for other rare conditions over the past decade. That track record helped build investor confidence heading into this trial’s results. It makes the scale of this week’s drop notable even by biotech standards.

Markets had priced in meaningful future revenue from this program ahead of the readout. The scale of the stock’s decline suggests investors read the missed endpoint as a clear setback rather than a mixed or ambiguous result. A trial that had come close to its goal typically produces a smaller, more contested market reaction than this one did.

What the Ultragenyx Angelman trial failure means

Researchers designed the Phase 3 trial to test whether the drug candidate produced measurable improvement against a specific clinical endpoint tied to Angelman syndrome symptoms. The trial did not achieve that primary endpoint, according to the company’s own disclosure. That kind of result typically forces a pharmaceutical company to choose a path. It can redesign its development program, pursue a narrower indication, or discontinue the candidate altogether.

Medicine vials in a laboratory setting representing the Ultragenyx Angelman trial failure

Biotech stocks routinely see sharp single-day drops on trial failures. Investors often price a drug’s entire commercial value into the stock well in advance of pivotal trial results. A negative readout can then erase most of the anticipated future revenue in one announcement.

Why rare disease trials carry this much risk

Angelman syndrome affects a small patient population, which makes recruiting large enough trial cohorts statistically challenging. Rare disease drug development has attracted growing investment in recent years, mainly because successful therapies can command premium pricing. That same rarity raises the risk that a single trial’s design or population will not generate a clear result.

Ultragenyx has other programs in its pipeline targeting different rare genetic conditions. The company’s broader business will depend on how those separate programs perform, independent of this specific setback.

How investors and patients are likely to respond

For shareholders, the stock’s decline reflects a swift repricing of the company’s near-term prospects rather than a judgment on Ultragenyx’s other pipeline assets. Sentiment around a company often suffers broadly following a high-profile Phase 3 miss, even when other programs remain unaffected. For patients and families affected by Angelman syndrome, the result is a setback in the search for a disease-modifying treatment. It does not necessarily end research in the field, since other companies and academic groups continue separate work on the condition.

Ultragenyx has not yet detailed whether it will pursue additional analysis of the trial data, attempt a follow-up study with a revised design, or discontinue the program entirely.

What the trial data showed on secondary measures

Pharmaceutical companies often look past a missed primary endpoint to see whether secondary measures still show a treatment signal worth pursuing. Ultragenyx has not yet published a detailed breakdown of secondary endpoint results from this trial. Analysts covering the company say that data will likely shape whether Ultragenyx pursues a redesigned study or moves on entirely. Similar rare disease trials have occasionally found a narrower patient subgroup that responded better than the overall study population, which can support a revised regulatory pathway in some cases.

Whether that pattern holds here remains unknown until Ultragenyx releases fuller data, which the company has not yet scheduled.

What happens next for the drug program

Companies facing a missed primary endpoint typically spend weeks reviewing secondary endpoint data and subgroup analyses before deciding on a path forward. Regulatory conversations with agencies like the FDA often follow before any public announcement of next steps. Investors should expect Ultragenyx to provide further detail in its next quarterly earnings update, or in a dedicated announcement once the internal review concludes.

The broader rare disease drug development sector is likely to watch closely. A Phase 3 miss on a closely-tracked program can influence how much capital flows toward similarly structured trials in adjacent rare conditions.

Questions about the trial and stock drop

  • What condition was the drug targeting? Angelman syndrome, a rare genetic neurological disorder.
  • How much did the stock fall? Ultragenyx shares plunged more than 46% following the announcement.
  • Did the trial meet its goal? No, the Phase 3 trial did not achieve its primary endpoint.
  • Is the drug program discontinued? The company has not confirmed whether it will discontinue, redesign, or continue the program.
  • Does this affect Ultragenyx’s other drugs? Not directly, though investor sentiment toward the company broadly may be affected.
  • Are other companies researching Angelman syndrome treatments? Yes, other companies and academic groups continue separate research into the condition.

Related coverage on Tamara News

See our coverage of September’s major class action settlements, GitLab’s earnings surge, and Broadcom’s Q4 revenue forecast.

Sources

  • CNBC — Stock market news for Sept. 4, 2026, covering major earnings movers. cnbc.com
  • ii.co.uk — US earnings season Q2 2026 roundup. ii.co.uk

10 Sep 2026
Bank building facade representing the WaFd EverBank reverse merger

A $3.9 Billion Bank Deal Just Rewrote the West Coast Banking Map

Categories Business

WaFd, a Pacific Northwest bank holding company, has entered into a $3.9 billion reverse merger with EverBank Financial Corp. The deal, announced September 8, 2026, will reshape the combined company’s footprint across the western and southeastern United States.

In a reverse merger, the smaller or less-publicly-traded party often ends up governing the resulting entity’s structure. That happens even though the larger partner’s brand may carry forward. WaFd and EverBank are still working out the exact governance and branding details as regulatory filings proceed.

WaFd traces its roots back more than a century as a Seattle-based thrift institution before expanding into a full-service regional bank. EverBank built its national presence primarily through digital banking products aimed at customers outside its traditional southeastern footprint. Combining the two brings together very different growth strategies under one holding structure.

WaFd operates branches across several Western states, giving it a physical retail presence that EverBank’s largely digital model does not replicate. Analysts point to that combination of branch banking and digital scale when explaining the strategic logic behind the deal. It goes beyond the raw dollar figures involved.

Bank executives on both sides have framed the deal publicly as complementary rather than defensive. Neither company has described itself as struggling ahead of the merger. That framing matters, since regulators and shareholders often scrutinize distressed mergers more closely than deals struck from a position of relative strength.

What the WaFd EverBank reverse merger actually changes

The deal combines WaFd’s West Coast retail and commercial banking footprint with EverBank’s national digital banking operations and southeastern presence. Together, the two create a combined institution with a broader geographic reach than either company had independently. The $3.9 billion valuation reflects EverBank’s scale as a digitally-focused bank that has grown its national deposit base in recent years.

Bank headquarters building representing the WaFd EverBank reverse merger deal

Bank mergers of this size typically require sign-off from federal banking regulators. Those include the Federal Reserve and the Office of the Comptroller of the Currency. That process can take months. It occasionally results in conditions attached to approval, such as divestitures in overlapping markets.

Why banks are consolidating again in 2026

The WaFd-EverBank deal is part of a broader wave of regional bank consolidation that has picked up through 2026. Mid-sized banks are weighing the cost of standalone technology investment and regulatory compliance against the scale advantages of combining with a partner. Regional banks in particular have faced pressure to match the digital banking capabilities of larger national players.

Analysts tracking the sector point to rising compliance costs and thin net interest margins as recurring drivers behind similar tie-ups this year. WaFd has not fully detailed the specific financial terms behind its rationale for this transaction in public filings as of early September.

What customers should expect

Bank mergers typically do not change existing account terms immediately. Customers of both institutions should expect continuity of service through the transition period, which regulatory review alone is likely to extend well into 2027. WaFd has completed prior acquisitions with limited disruption to existing depositors, maintaining separate branding for a period before full integration.

Employees and depositors will likely receive formal notices as the transaction moves through regulatory review. That notice process is standard practice for deals of this size under US banking law.

How this deal compares with other 2026 bank mergers

Regional banking has seen a wave of tie-ups this year, and the WaFd-EverBank transaction is among the largest by dollar value. Several smaller regional players have pursued similar combinations, citing the same pressures: rising technology spend, thin margins and competition from digitally-native banking apps. Industry observers say the pace of consolidation could continue into 2027 if interest rates stay elevated and margin pressure persists. Community banking advocates have raised concerns that consolidation reduces the number of independent local lenders, particularly in smaller markets.

WaFd has not said whether it expects to close any physical branches as part of the integration. That detail typically emerges later in the regulatory review process.

What happens next for the combined bank

The merger now moves into regulatory review, where federal banking agencies will assess competitive overlap, capital adequacy and consumer protection considerations before granting approval. Both companies will need shareholder approval in parallel with the regulatory process, a step typically scheduled once filings are further along.

If approved on a typical timeline, the combined institution would likely complete integration sometime in 2027. That estimate is based on how comparable regional bank mergers have played out in recent years.

Questions about the WaFd-EverBank deal

  • How much is the deal worth? The transaction is valued at $3.9 billion.
  • When was it announced? September 8, 2026.
  • What is a reverse merger? A deal structure where the surviving legal entity is not always the larger or more well-known of the two combining companies.
  • Will customer accounts change immediately? No, existing account terms typically remain unchanged during the transition period.
  • Does the deal still need approval? Yes, federal banking regulators and shareholders of both companies must approve the transaction.
  • When might the merger close? Based on comparable deals, completion in 2027 is a reasonable expectation, pending regulatory review.

Related coverage on Tamara News

See our coverage of Palo Alto Networks’ acquisition spree, the Bank of Canada’s rate hold decision, and the upcoming Bank of England September vote.

Sources

  • CNBC — Stock market news for Sept. 4, 2026, covering the week’s major acquisitions. cnbc.com
  • Yahoo Finance — Company earnings and deal calendar. finance.yahoo.com

1 … 74 75 76 77 78 … 241